Skip to content
Open access

Five-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves.

Sep 2026 · JACC: Cardiovascular Interventions · 0 citations · 21 references
Medicine

TL;DR

In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.

Abstract

Background

Long-term outcomes of the self-expanding intra-annular Portico transcatheter aortic valve are not known.

Objectives

This study aimed to report the 5-year outcomes of the PORTICO IDE randomized controlled trial.

Methods

This multicenter trial randomized (1:1) patients with severe symptomatic aortic stenosis at high/extreme surgical risk to transcatheter aortic valve replacement (TAVR) with the self-expanding intra-annular valve (study valve) or Food and Drug Administration-approved commercially available valves (CAVs; balloon-expandable or self-expanding supra-annular platforms). Assessments of the primary safety endpoint (30 days) and the primary efficacy endpoint (1 year) have been previously reported. Prespecified clinical outcomes and hemodynamic valve parameters are presented through 5 years.

Results

We randomized 750 eligible patients (mean age: 83 years, 52.7% female) to the study valve (n = 381) or CAV (n = 369). Compared with CAV, the study valve showed similar 5-year all-cause mortality or stroke (55.6% vs 51.3%, P = 0.42). Cardiovascular mortality was numerically higher in the study valve group compared with the CAV group (33.4% vs 25.8%; P = 0.06). Naïve permanent pacemaker implantation was higher in the study valve group (36.6%) than the CAV group (20.3%; P < 0.0001) at 5 years. At 5 years, the study valve showed a lower mean transvalvular gradient (7.2 ± 3.0 vs 9.5 ± 6.5 mm Hg, P = 0.008), but similar valve area (1.78 ± 0.45 vs 1.71 ± 0.51 cm2, P = 0.40) compared to CAV.

Conclusions

In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.

Read PDF

Similar papers

Open access Sep 2026

Clinical Outcomes and Valve Performance of Intra-Annular Self-Expanding Transcatheter Aortic Valve in Valve-in-Valve Procedures: Insights From the NAViV Registry.

BACKGROUND Most evidence for transcatheter aortic valve replacement (TAVR) for valve-in-valve procedures comes from balloon-expandable and supra-annular self-expanding valves. However, data on intra-annular self-expanding valves remain limited. The objectives of this registry were to evaluate the short- and midterm out...

Jorge F. Chavez, G. Tirado-Conte, Y. Kobari et al. · 0 citations
Open access Aug 2026

Outcomes of Supra-Annular vs Intra-Annular Self-Expanding Valves in Valve-In-Valve Transcatheter Aortic Valve Replacement.

BACKGROUND Self-expanding valves appear to have superior hemodynamics compared with balloon-expandable valves for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR). OBJECTIVES This study aimed to compare echocardiographic and clinical outcome data between supra-annular self-expanding valves (SASEVs) an...

Kuljit Singh, E. Dababneh, M. Matta et al. · 1 citation
Sep 2026

Long-term outcomes after balloon- or self-expandable transcatheter aortic valve replacement in small aortic annuli.

The need for further investigations using larger cohorts and contemporary devices to validate long-term comparative outcomes of BEV and SEV in patients with SAA is underscore the need for further investigations using larger cohorts and contemporary devices to validate long-term comparative outcomes.

T. Ryuzaki, Kentaro Hayashida, Kei Kamata et al. · 0 citations
Open access Aug 2026

Redo-Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis.

In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR and support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.

Toby Rogers, V. Bapat, S. Chetcuti et al. · 1 citation
Sep 2026

Impact of Aortic Annulus Size on Clinical and Hemodynamic Outcomes of Transcatheter Aortic Valve Implantation With the Navitor Valve

Patients with small aortic annuli undergoing transcatheter aortic valve implantation (TAVI) are at risk of higher residual transvalvular gradients. Evidence on the performance of new‐generation intra‐annular self‐expanding valves in this anatomical setting remains limited.

M. Casenghi, S. Corradetti, P. Paolisso et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.